The EDC is live today — see what ships now
All studies
NCT06808477From ClinicalTrials.govRecruiting

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

A Randomized, Blinded, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 in HVs and Adult Patients With AD

  • Atopic Dermatitis

At a glance

Phase
Phase 1
Study type
Interventional
Sponsor
Bambusa Therapeutics
Enrolment target
237
Started
27 February 2025
Main results due
28 February 2027
Study sites
14
Registry updated
29 September 2026

Can you take part?

  • Ages 18 years to 72 years.
  • Open to any sex.
  • Healthy volunteers can take part.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria
Key Inclusion Criteria

1. Negative pregnancy tests for women of childbearing potential.
2. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.
3. Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.
4. Adequate contraception use (for men and women of childbearing potential).

Key Inclusion Criteria (Parts A, B, and D)

1. Age of 18-65 years.
2. Body mass index of 18 to 32 kg/m², weight capped at 120 kg.
3. No clinically significant abnormalities or history of relevant diseases.

Key Inclusion Criteria (Parts C and E only)

1. Age of 18-72 years.
2. Body mass index ≥16 kg/m², weight capped at 125 kg.
3. Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.
4. Moderate to severe atopic dermatitis
5. Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3
6. Atopic lesions cover ≥10% of body surface area (BSA)
7. Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.

Key Exclusion Criteria

1. Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.
2. History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.
3. Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.
4. Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.
5. Abnormal Electrocardiogram (ECG) findings
6. History of drug/alcohol abuse in the past 2 years.
7. Donated \>500mL blood within 2 months of screening.
8. History of severe allergic reactions or hypersensitivity.

Key Exclusion Criteria (Parts A, B, and D only)

1\. History of atopic dermatitis

Key Exclusion Criteria (Parts C and E only)

1. Skin diseases other than atopic dermatitis, significant tattoos, or scarring.
2. Receipt of immunoglobulin or blood products within 30 days.
3. Atopic dermatitis with ocular symptoms or chronic ocular steroid use.
4. Chronic pruritus from conditions other than atopic dermatitis.
5. Acute/treated infections or chronic skin infections.
6. Current use of sedating antihistamines or corticosteroids.

What this study is about

In the sponsor’s own words, from the registry.

This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Study sites(14)

  • First OC Dermatology

    Irvine, California, United States

    Recruiting

  • OptiSkin Medical

    New York, New York, United States

    Recruiting

  • Equity Medical, LLC

    The Bronx, New York, United States

    Recruiting

  • Fremantle Dermatology

    Fremantle, Western Australia, Australia

    Recruiting

  • Linear Clinical Research

    Perth, Western Australia, Australia

    Completed

  • Optimal Clinical Trials Central Auckland

    Grafton, Auckland, New Zealand

    Recruiting

  • Aotearoa Clinical Trials

    Otahuhu, Auckland, New Zealand

    Withdrawn

  • Pacific Clinical Research Network (PCRN) - Auckland

    Takapuna, Auckland, New Zealand

    Recruiting

  • Optimal Clinical Trials Ltd - Christchurch

    Christchurch, New Zealand

    Recruiting

  • Pacific Clinical Research Network (PCRN) Wellington

    Upper Hutt, New Zealand

    Recruiting

  • Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi

    Lodz, Poland

    Recruiting

  • Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie

    Rzeszów, Poland

    Recruiting

  • Państwowy Instytut Medyczny MSWiA

    Warsaw, Poland

    Recruiting

  • Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska

    Wroclaw, Poland

    Recruiting

Showing 14 of 14 sites. 12 of the 14 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT06808477. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) | Trialion